Concepedia

Meg Annan

MA

4

Publications

424

Citations

4

H-Index

1993

Active since

Affiliations

GlaxoSmithKline (United States)(Current)

Harvard University

The University of Texas MD Anderson Cancer Center

Brigham and Women's Hospital

University of Pennsylvania

Meg Annan is an author at GlaxoSmithKline (United States) specializing in medicine, pharmacology, and pathology.

Top concepts

Publications per year

1993–2019

4

Publications

4

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

Sarina A. Piha‐Paul, Christine L. Hann, Christopher A. French et al. · JNCI Cancer Spectrum · 2019 · 196 citations · Full text

Reduction of Signal Suppression Effects in ESI-MS Using a Nanosplitting Device

Eric T. Gangl, Meg Annan, Neil Spooner et al. · Analytical Chemistry · 2001 · 180 citations

, , +21

Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers

Peter J. O’Dwyer, Sarina A. Piha‐Paul, Christopher A. French et al. · Cancer Research · 2016 · 37 citations

, , +17

Trimethylsilyl group migration in the mass spectra of trimethylsilyl ethers of cholesterol oxidation products. product ion characterization by linked-scan tandem mass spectrometry

Meg Annan, P.W. Lequesne, Paul Vouros · Journal of the American Society for Mass Spectrometry · 1993 · 11 citations

Rows per page

1–4 of 4